EUVIMEDEUVIMED entdecken
Crossref

Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis

Jagadeswara Rao Earla iD, Jieni Li, George J Hutton, Michael L Johnson, Rajender R Aparasu iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Jagadeswara Rao Earla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: AHRQ HHS, Agency for Healthcare Research and Quality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective This study compared the adherence trajectories of fingolimod (FIN), teriflunomide (TER), and dimethyl fumarate (DMF) users with multiple sclerosis (MS) as there is limited evidence regarding the comparative adherence patterns of different oral disease‐modifying agents (DMAs).

Design

A retrospective cohort study Data Source 2015–2019 IBM MarketScan Commercial Claims Database. Patients Adults (≥18 years) with MS (International Classification of Diseases [ICD]‐9/10‐Clinical Modification [CM]:340/G35) diagnosis and ≥1 DMA prescription.

Intervention

Incident FIN‐, TER‐, or DMF use based on the index DMA with 1 year of washout period.

Measurements

The DMA adherence trajectories based on the proportion of days covered (PDC) were examined using the Group‐Based Trajectory Modeling (GBTM) one year after the treatment initiation. Generalized boosting models (GBM)‐based inverse probability treatment weights (IPTW) were incorporated in multinomial logistic regression to assess the comparative adherence trajectories across oral DMAs with FIN group as a reference category. Measurements and Main Results The study cohort consisted of 1913 patients with MS who were initiated with FIN (24.2%, n = 462), TER (24.0%, n = 458), and DMF (51.9%, n = 993) during 2016–2018. The adherence rate (PDC ≥ 0.8) among FIN, TER, and DMF users was found to be 70.8% ( n = 327), 59.6% ( n = 273), and 61.0% ( n = 606), respectively. The GBTM grouped patients into three adherence trajectories: Complete Adherers—59.1%, Slow Decliners—22.6%, and Rapid Discontinuers—18.3%. The multinomial logistic regression model involving GBM‐based IPTW revealed that DMF (adjusted odds ratio [aOR]: 2.32, 95% confidence interval [CI]:1.57–3.42) and TER (aOR: 2.50, 95% CI: 1.62–3.88) users had higher odds to be rapid discontinuers relative to FIN users. In addition, TER users were more likely (aOR: 1.50, 95% CI: 1.06–2.13) to be slow decliners compared with FIN users.

Conclusion

Teriflunomide and DMF were associated with poorer adherence trajectories than FIN. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs to optimize the management of MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisAdultHumansRetrospective StudiesFingolimod HydrochlorideCrotonatesDimethyl FumarateImmunosuppressive AgentsMedication AdherenceHydroxybutyratesNitrilesToluidines

Stichwörter der Autor:innen

adherencemultiple sclerosisreal-world evidencetreatment pattern

Substanzen

Fingolimod HydrochlorideCrotonatesDimethyl FumarateImmunosuppressive AgentsteriflunomideHydroxybutyratesNitrilesToluidines

Autor:innen und Institutionen

  • Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA.
  • Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Jagadeswara Rao Earla, Rajender R Aparasu

Förderung

  • AHRQ HHS
  • Agency for Healthcare Research and Quality

Zitieren

APA

Earla, J. R., Li, J., Hutton, G. J., Johnson, M. L., & Aparasu, R. R. (2023). Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2810

Vancouver

Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2810

BibTeX
@article{Earla2023,
  author = {Earla, Jagadeswara Rao and Li, Jieni and Hutton, George J and Johnson, Michael L and Aparasu, Rajender R},
  title = {Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2810}
}
Kostenlos starten →